Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.16.3.1 (
ceruloplasmin
)
5,074
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The ability of
ceruloplasmin
, an important serum antioxidant, to reduce the vulnerability of the isolated rat heart to reperfusion arrhythmias has been investigated. Bovine plasma
ceruloplasmin
was purified by chromatography on aminoethyl-agarose. Isolated rat hearts were submitted to 15 min of regional ischemia and 10 min of reperfusion. The dose-effect relationship and the role of
ceruloplasmin
conformational integrity in cardioprotection were established by treatment of ischemic hearts with
ceruloplasmin
at various concentrations (0.25, 0.5, 1, and 2 microM) and at different degrees of conformational integrity (A610/A280 = 0.02, 0.04, and 0.06), 5 min before reperfusion. Deferoxamine (20-500 microM) was used as a positive control. As negative controls we used chemically inactivated
ceruloplasmin
(1 microM), heat-denatured
ceruloplasmin
(1 microM), and albumin (1-4 microM). In the control group during the first 5 min of reperfusion, the incidence of total
ventricular fibrillation
was 100% and of irreversible
ventricular fibrillation
was 83%. The incidence of reversible and irreversible
ventricular fibrillation
was significantly decreased in the
ceruloplasmin
-treated groups in both a dose and molecular integrity dependent manner. Ceruloplasmin had no effect on the incidence of ventricular tachycardia. Deferoxamine reduced the incidence of
ventricular fibrillation
to the same degree as
ceruloplasmin
but at concentrations much higher than those of
ceruloplasmin
. Chemically inactivated
ceruloplasmin
, heat-denatured
ceruloplasmin
, and albumin had no protective effects on reperfusion-induced arrhythmias.
...
PMID:Antiarrhythmic effects of ceruloplasmin during reperfusion in the ischemic isolated rat heart. 874 74